Back to All News

Baumann receives National Cancer Institute award

Washington University School of Medicine
Dr. Baumann

Brian C. Baumann, MD, assistant professor of radiation oncology at Washington University School of Medicine in St. Louis and a radiation oncologist at Siteman Cancer Center, has been awarded a 2021 Cancer Clinical Investigator Team Leadership Award from the National Cancer Institute (NCI).

The award, given this year to 10 researchers nationally, recognizes outstanding clinical investigators at NCI-Designated Cancer Centers who participate extensively in NCI-funded clinical trials and whose leadership and activities promote a successful culture of collaborative clinical research.

“These awardees, five men and five women, have outstanding leadership skills and will be conducting clinical trials in a range of adult cancer types, testing new cancer therapies, developing critical biomarkers and moving the field of personalized medicine forward,” said Sheila Prindiville, MD, director of NCI’s Coordinating Center for Clinical Trials. “Additionally, these awardees will be educating and mentoring the next generation of clinical trialists, working to enhance participation of underserved populations in clinical trials and improve community engagement and access.”

Separately, Baumann recently has been:

  • Elected co-chair of the NCI’s Bladder Cancer Task Force. He is the lead radiation oncologist on the committee, which reviews cooperative group bladder cancer clinical trials and makes funding recommendations.
  • Named to the board of directors of the National Association for Proton Therapy (NAPT), an organization for which he also serves on the Physician Advisory, Government Relations and Education committees.
  • Named to the education committee of the 2021 annual meeting of the American Society for Radiation Oncology (ASTRO).

Baumann, who also is chief of the genitourinary service in the Department of Radiation Oncology at the School of Medicine, has his principal clinical and academic focus in genitourinary oncology, sarcomas and skin cancers. He also researches the role of proton therapy in oncology and improving treatment options for patients with limited metastases or relapsed disease.